(Total Views: 345)
Posted On: 01/17/2021 11:04:41 AM
Post# of 36564
As Joe said in the CC announcement:
In addition, I will
update everyone on our progress and timing on the NuGenerex Immuno-Oncology
Nasdaq listing now that our third-party valuation analysis has been completed with a
value estimated at over $500 million. This third-party valuation report is the last piece of
information required to enable us to set the price per share to meet the standards for
the Nasdaq.
In addition, I will
update everyone on our progress and timing on the NuGenerex Immuno-Oncology
Nasdaq listing now that our third-party valuation analysis has been completed with a
value estimated at over $500 million. This third-party valuation report is the last piece of
information required to enable us to set the price per share to meet the standards for
the Nasdaq.
(2)
(0)
